Peptide Profile
GLP-2 TZEP
Dual GIP/GLP-1 receptor agonist
CLINICAL DEVELOPMENT STAGE:
Approved
GLP-2 TZEP is the research designation used by Unscripted for tirzepatide (LY3298176), a synthetic 39-amino-acid peptide that acts as a dual agonist of the GIP and GLP-1 receptors. It is studied for its effects on incretin signaling, glucose regulation, appetite and energy intake, body-weight regulation, and broader cardiometabolic pathways.
Compound Overview
Molecular Formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight
4813.45 g/mol
CAS Number
2023788-19-2
Classification
Dual GIP/GLP-1 receptor agonist
Regulatory Status
RESEARCH USE ONLY · NOT FDA APPROVED
Targets / Receptors
Glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R).
Research Focus
Obesity and body-weight regulation; type 2 diabetes and glycemic control; cardiovascular and renal outcomes; metabolic dysfunction-associated steatotic liver disease (MASLD); obstructive sleep apnea; and broader cardiometabolic risk-factor research.
Mechanism of Action
GLP-2 TZEP corresponds to tirzepatide, a synthetic peptide engineered to activate two metabolically relevant receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Tirzepatide is therefore classified as a dual GIP/GLP-1 receptor agonist.
Tirzepatide’s activity at the GIP and GLP-1 receptors is associated with pathways involved in glucose-dependent insulin secretion, glucagon regulation, appetite and food-intake signaling, and broader metabolic regulation. Its simultaneous activity at both incretin receptors distinguishes it from compounds that selectively target the GLP-1 receptor alone.
The compound’s biological activity reflects the integrated effects of GIP and GLP-1 receptor signaling rather than the action of either pathway in isolation. Research has also shown that tirzepatide has a distinct signaling profile at these receptors, and the relative contribution of each receptor pathway to its observed metabolic effects remains an active area of investigation.
Research Evidence
Clinical evidence for GLP-2 TZEP (tirzepatide) includes multiple large randomized trials across obesity and metabolic disease. The SURPASS program demonstrated significant improvements in glycemic control and body weight in adults with type 2 diabetes, while the SURMOUNT program showed substantial and sustained body-weight reductions in adults with obesity or overweight.
Research has since expanded beyond weight and glycemic outcomes. Phase 3 trials in adults with obesity and moderate-to-severe obstructive sleep apnea found reductions in apnea-hypopnea index, body weight, and hypoxic burden. A phase 2 trial in metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis also found higher rates of MASH resolution without worsening of fibrosis compared with placebo.
More recent cardiovascular outcomes research has also evaluated tirzepatide in patients with type 2 diabetes and established atherosclerotic cardiovascular disease, extending the evidence base beyond glucose and weight endpoints. Overall, tirzepatide has one of the more extensive clinical-development programs among dual incretin receptor agonists, with research spanning glycemic control, obesity, sleep apnea, liver disease, and cardiovascular outcomes.
Safety & Limitations
Clinical studies of tirzepatide have identified gastrointestinal adverse events, including nausea, diarrhea, vomiting, constipation, and abdominal symptoms, as the most commonly reported tolerability issues. FDA prescribing information also identifies important risks including pancreatitis, gallbladder disease, acute kidney injury associated with volume depletion, hypersensitivity reactions, hypoglycemia in certain treatment settings, and diabetic retinopathy complications in susceptible patients.
Tirzepatide carries a boxed warning based on thyroid C-cell tumors observed in rats. Whether this finding translates to humans remains unknown.
Published clinical safety data apply to studied, regulated tirzepatide drug products and study populations. They should not be assumed to establish the safety, sterility, clinical suitability, or therapeutic effectiveness of GLP-2 TZEP supplied as a research-use-only material. Long-term outcomes and the relative contribution of GIP versus GLP-1 receptor activity to specific effects also remain areas of continued investigation.
Key References
Coskun T, Sloop KW, Loghin C, et al.
Molecular Metabolism. 2018;18:3–14.
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Tirzepatide Once Weekly for the Treatment of Obesity
New England Journal of Medicine. 2022;387:205–216.
Malhotra A, Grunstein RR, Fietze I, et al.
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
New England Journal of Medicine. 2024;391:1193–1205.
Nicholls SJ, Pavo I, Bhatt DL, et al.
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
New England Journal of Medicine. 2025;393:2409–2420.
Last scientifically reviewed: August 15, 2026
